The significance of height loss in postmenopausal women. The results from GO Study.
Int J Clin Pract. 2021 Jan 07;:e14009 Authors: Pluskiewicz W, Adamczyk P, Drozdzowska B
The aim of the study was the assessment of clinical significance of height loss (HL) in female population. MATERIAL: The study cohort was recruited from GO Study. Data from 1735 postmenopausal women aged over 55 years (mean age 68.15±8.16 years) were analyzed. METHODS: Data on clinical risk factors for osteoporosis and fractures were collected. Bone densitometry at hip was performed using a device Prodigy (GE, USA). Height was established using stadiometer and was compared with maximal height in early adulthood. RESULTS: The mean HL was 3.9±3.2 cm. HL was significantly higher in women with fractures in comparison to those without fracture (4.9±3.6 cm vs. 3.4±2.8 cm; p<0.0001). HL increased with the number of fractures, and was 4.1±3.2 cm, 5.3±3.5 cm and 6.7±4.1 cm in women with one, two and three or more fractures, respectively. Women with spine fractures presented with HL higher in comparison to all the other subjects (6.3±3.9 versus 3.6±2.9 cm, p<0.0001) and women with all non-spine fractures (6.3±4.0 versus 4.0±3.0 cm, p<0.0001). In women with steroid use and falls HL was significantly greater than in subjects without this factor. HL correlated significantly with age and BMI (positively) and current height (negatively). Mean T-score for FN BMD was -1.75±0.9 and correlate significantly with HL (r=-0.21, p<0.0001). For the HL threshold above 4 cm, the fracture incidence was above 50%. CONCLUSION: Height loss value is a simple and very informative measure describing fracture risk and functional status in postmenopausal women. HL exceeding 4 cm is related to fracture probability above 50%. PMID: 33411978 [PubMed - as supplied by publisher]